Given the broad-spectrum organ safety of nobiletin demonstrated in animal models in vivo41, 42, 43, our present work suggests that nobiletin, as combination therapy, may be a good candidate for studies in vivo to reverse ABCB1-medicated drug resistance in cancer therapy. The gene discussed is ABCB1; the disease is cancer.